Q-omics provides the consensus-scored TARS2 profile across patient tissues and cancer cell-line models. TARS2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TARS2 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, TARS2 RNA expression shows 18,968 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, KIRC, and ACC as cancer lineages where TARS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TARS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TARS2 survival associations across molecular data types. TARS2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TARS2 RNA expression–survival associations across cancer types. High TARS2 expression shows unfavorable associations in KICH, UVM, LGG, KIRP and UCEC, but favorable associations in SCLC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for TARS2 RNA expression.
This table summarizes TARS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TARS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TARS2 shows higher tumor expression in KIRC, COAD, HNSC, BLCA, LUAD and LUSC. The KIRC box plot shows higher TARS2 RNA expression in tumor versus normal tissue (log2 FC = +0.462, t-test p < 0.001).
This table shows molecular features associated with TARS2 in patient tissues and cancer cell lines. In patient samples, TARS2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TARS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
